Latest news

Results advance a high-value oncology asset towards regulatory submission and Day-1 launches across priority global markets, including the US.  Zug, Switzerland, 22nd July 2026 — Adalvo today announced positive results...

Switzerland, 20 July 2026 — Adalvo has entered into a partnership with humanitarian aid organization Direct Relief to expand access to essential medicines for underserved communities worldwide. The partnership marks...

As emergency relief efforts continue following the earthquake in Venezuela, Adalvo is supporting UNICEF’s work on the ground. At times like this, access to healthcare and essential support is critical....

Adalvo announces the first-to-market launch of generic Macitentan 10 mg film-coated tablets in Estonia, Latvia and Lithuania, in partnership with Norameda — the first generic version of the therapy available...

Adalvo and Amneal Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has accepted for review two Abbreviated New Drug Applications (ANDAs) filed at NCE-1 for generic tirzepatide...

Adalvo has completed pilot bioequivalence studies for generic Letermovir film-coated tablets. The programme will now advance into pivotal bioequivalence studies, ahead of filings in multiple markets.  As a high-barrier antiviral...

Adalvo is preparing filings for its generic linagliptin/metformin fixed-dose combination (FDC) tablet across multiple regions, including Europe via the DCP. The move advances the programme towards global market entry.  It...

Adalvo is submitting its dossier for generic dolutegravir film-coated tablets through the European DCP.  Dolutegravir — marketed as Tivicay (ViiV Healthcare) — is a cornerstone of WHO-recommended first-line HIV treatment...

Adalvo, the global B2B pharmaceutical company specialising in dossier development and out-licensing across 140+ markets, today announces the appointment of Rannveig Borg Sigurðardóttir as Chief Legal Officer. Based in Switzerland...

We are excited to announce we have received DCP approval across EU markets for our generic tacrolimus topical ointment (0.03% and 0.1% strengths), further expanding our dermatology portfolio.  Based on...

Adalvo has successfully completed the pivotal fed study for Avatrombopag 20 mg film-coated tablets. This milestone supports the progression towards regulatory submission and Day-1 launches across the US, EU and...

Adalvo is pleased to announce the signing of two new strategic distribution partnerships with Blanver, a prominent Brazilian pharmaceutical company, for two technically differentiated, value-add oncology products. These agreements further...

Adalvo and Cipla are pleased to announce the expansion of their strategic partnership with the launch of Vyfocis® capsules in South Africa. The launch represents a significant step in both...

Adalvo is well positioned for Day-1 launches of their generic Tafamidis 61mg soft gel capsules, supported by strong development and IP strategy. Based on the reference brand Vyndamax, Tafamidis is...

Adalvo has commenced pivotal bioequivalence (BE) studies for generic Binimetinib film coated tablets. It’s a significant milestone in bringing an affordable version of this important oncology therapy to patients in...

Adalvo, one of Europe's leading B2B pharmaceutical companies, today announced the appointment of Joan Fusté and Nick Kelly to senior executive roles, effective 1 January 2025. The appointments reflect Adalvo's...

Adalvo is proud to announce the first-to-market launch of generic Brivaracetam film-coated tablets in Croatia, in partnership with one of Europe’s leading generic pharmaceutical companies.  This milestone marks the first...

Adalvo, a leading global pharmaceutical company specialising in the development and commercialisation of complex generics, 505(b)(2), peptides and GLP-1s, today announced an exclusive global development, licence and supply collaboration for...